GlassScriptPhysician profile
Tamera M Pace
NPI 1427045897
$16,142.91
in general payments reported to CMS, 2019-2025
61 companies · $2,238 in 2025
The $2,238 reported for 2025 was more than what 94% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,762 · 2022: $3,795 · 2023: $3,463 · 2024: $2,886 · 2025: $2,238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,459 · Education: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,459.10 |
| Education | $126.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,757.53 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,416.73 | 2021-2025 | Xifaxan, Trulance |
| Abbvie INC. | $1,145.22 | 2021-2025 | |
| Pfizer INC. | $970.45 | 2021-2025 | |
| Lilly USA, LLC | $932.12 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $895.41 | 2021-2025 | Repatha, Otezla, Otezla |
| Otsuka America Pharmaceutical, INC. | $653.06 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $597.28 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $573.32 | 2021-2024 | Livalo, Seglentis |
| Glaxosmithkline, LLC. | $511.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $472.09 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.12 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $405.37 | 2021-2025 | Jardiance, Ofev, Tradjenta |
| Astellas Pharma US INC | $312.86 | 2023-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $309.39 | 2021-2023 | Belsomra, Steglatro |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Pace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.